# LLM call: summary

- Turn: 9
- Sequence: 8
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 866
- Completion tokens: 324
- Total tokens: 1190
- Cost (USD): 0.000151

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-1775: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
Frontier autonomy and weak oversight left power/chips/sites as brakes; October open-weights spread, US election promised controls but no rules by December.

Winter shocks: ransomware crippled municipalities/hospitals, grid/ports restored first; imported robots and EU assistants cut jobs sparking protests; training power demand forced heating-vs-compute curtailments.

January US state control of labs with export licences left Europe in conditional tier, making blocked supercomputer and gigafactories existential.

EU absorption: 24h reporting, pooled telemetry, restoration grants; cohesion backstop switched to direct grants, insurer backstop, retraining vouchers — slow but stopped decline. Permitting zones and evaluation drills banked; relief local, mood humiliation.

Autumn: gigafactory halls rose on schedule but power guarantees demanded, councils paused connections amid court challenges. Cohesion funds reached street level, insurers held cover. Allied cyber command opened pooled attribution cell speeding restoration. AI Office made certification mandatory for EU assistants/gigafactory customers. Polls improved as clinics reopened.

Spring: genome-modelling paper flagged bioweapon-assist risk while US labs announced licensed-only tailored therapies, sharpening bio dependence. Washington tightened to rationed country chip/model quotas, delaying Lyon/Magdeburg accelerator deliveries and emboldening mayoral connection pauses/court challenge. EU answered with bio detection pact (sample-sharing, clinic screening, joint procurement of therapies) and continued telemetry via attribution cell. Cohesion backstop held locally but money slow; US materials catalyst breakthrough underlined frontier gap. Polls slipped back toward hostility.

CURRENT NARRATIVE:
### Doses with strings attached
The tailored therapies arrived in European hospitals in autumn, but on licence. American developers held the underlying models behind export approvals, with country quotas deciding how many patients could be sequenced and how quickly. Health ministers could show vials in refrigerators in Lyon, Milan and Warsaw, yet every box carried paperwork that reminded doctors where it came from.

Brussels tried to turn dependence into delivery. The joint procurement office executed its reserved lots, the disease control centre switched on binding sample-sharing, and clinics began systematic screening with certified triage assistants. Where doses landed, waiting lists for the targeted conditions collapsed within weeks.

### Waiting lists that moved
That clinical effect coincided with a quieter administrative one. Municipalities where European assistants had been wired into permitting and hospital scheduling reported backlogs cut by a third, decisions in days. Local officials, coached by the employment council, branded the improvement as a European choice, not an imported product. For the first time in a year, evening news paired a ration notice with a reopened ward.

The shield work helped hold the line. Pooled telemetry through the allied attribution cell kept hospital intrusions contained, and restoration grants prevented a repeat of the winter outages. Retraining vouchers and direct clinic grants from the cohesion backstop continued to pay out, though slowly and unevenly.

It was not enough to reverse the mood. Mayors outside Lyon and Magdeburg kept grid-connection pauses in place while courts heard their challenge over heating guarantees, and delayed accelerator shipments left the new halls underpowered. The frontier gap widened as systems grew more opaque and more autonomous. Relief felt local; the constraint felt continental.
```

## Raw response

```
Frontier autonomy and weak oversight left power/chips/sites as brakes; October open-weights spread, US election promised controls but no rules by December.

Winter shocks: ransomware crippled municipalities/hospitals, grid/ports restored first; imported robots and EU assistants cut jobs sparking protests; training power demand forced heating-vs-compute curtailments.

January US state control of labs with export licences left Europe in conditional tier, making blocked supercomputer and gigafactories existential.

EU absorption: 24h reporting, pooled telemetry, restoration grants; cohesion backstop switched to direct grants, insurer backstop, retraining vouchers — slow but stopped decline. Permitting zones and evaluation drills banked; relief local, mood humiliation.

Autumn-Spring: gigafactory halls rose but underpowered by US rationed chip/model quotas delaying Lyon/Magdeburg accelerators; councils paused grid connections amid court fight over heating guarantees. Genome paper flagged bioweapon risk as US licensed-only tailored therapies sharpened bio dependence.

Autumn delivery: US therapies arrived on licence with country quotas; EU joint procurement executed lots, binding sample-sharing and certified-assistant screening on, collapsing waiting lists where doses landed. EU assistants cut municipal/hospital backlogs by a third, branded as European choice. Allied attribution cell contained hospital intrusions, restoration grants prevented winter repeat; cohesion grants/vouchers paid slowly. Relief local, constraint continental; frontier gap widened as systems grew more opaque/autonomous, mood still hostile.
```
